---
figid: PMC4900422__cohem-23-402-g002
figtitle: Constitutive CBM signaling in B- and T-cell malignancies
organisms:
- NA
pmcid: PMC4900422
filename: cohem-23-402-g002.jpg
figlink: /pmc/articles/PMC4900422/figure/F1/
number: F1
caption: Constitutive CBM signaling in B- and T-cell malignancies. Underlying mechanisms
  include (a) mutations in CD79A or CD79B and CARMA1/CARD11, and self-antigen recognition,
  (b) self-antigen recognition or mutations upstream of BTK, (c) germline mutations
  in CARMA1, (d) generation of a MALT1-API2 fusion protein that activates the classical
  (NF-κB1) and nonclassical (NF-κB2) pathway, (e, f) gain-of function mutations in
  PLCγ1, PKCβ, or CARMA1, and in frame mutations of the T-cell co-receptor CD28 with
  ICOS or CTLA-4. In all figure panels, recurrent mutations are indicated with a yellow
  star. ABC, activated B-cell; ATLL, acute T-cell leukemia/lymphoma; BENTA, B-cell
  expansion with NF-κB and T-cell anergy; BCR, B-cell receptor; CBM, CARMA1/BCL10/MALT1;
  CTLA-4, cytotoxic T lymphocyte-associated protein 4; DLBCL, diffuse large B-cell
  lymphoma; ICOS, inducible costimulator; MALT, mucosa-associated lymphoid tissue;
  MCL, mantle cell lymphomas; PKC, protein kinase C; TCR, T-cell receptor.
papertitle: Role of the CARMA1/BCL10/MALT1 complex in lymphoid malignancies.
reftext: Mélanie Juilland, et al. Curr Opin Hematol. 2016 Jul;23(4):402-409.
year: '2016'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9175533
figid_alias: PMC4900422__F1
figtype: Figure
organisms_ner:
- Danio rerio
- Homo sapiens
redirect_from: /figures/PMC4900422__F1
ndex: dd981d39-deb2-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4900422__cohem-23-402-g002.html
  '@type': Dataset
  description: Constitutive CBM signaling in B- and T-cell malignancies. Underlying
    mechanisms include (a) mutations in CD79A or CD79B and CARMA1/CARD11, and self-antigen
    recognition, (b) self-antigen recognition or mutations upstream of BTK, (c) germline
    mutations in CARMA1, (d) generation of a MALT1-API2 fusion protein that activates
    the classical (NF-κB1) and nonclassical (NF-κB2) pathway, (e, f) gain-of function
    mutations in PLCγ1, PKCβ, or CARMA1, and in frame mutations of the T-cell co-receptor
    CD28 with ICOS or CTLA-4. In all figure panels, recurrent mutations are indicated
    with a yellow star. ABC, activated B-cell; ATLL, acute T-cell leukemia/lymphoma;
    BENTA, B-cell expansion with NF-κB and T-cell anergy; BCR, B-cell receptor; CBM,
    CARMA1/BCL10/MALT1; CTLA-4, cytotoxic T lymphocyte-associated protein 4; DLBCL,
    diffuse large B-cell lymphoma; ICOS, inducible costimulator; MALT, mucosa-associated
    lymphoid tissue; MCL, mantle cell lymphomas; PKC, protein kinase C; TCR, T-cell
    receptor.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - bcr
  - ighv1-2
  - cd28
  - cd79a
  - cd79b
  - malt1
  - malt2
  - prkcbb
  - lima1a
  - bcl10
  - nfkb1
  - nfkb2
  - FH
  - CLEC4D
  - CARD11
  - ABCB6
  - ICOS
  - CTLA4
  - TRBV20OR9-2
  - TRA
  - TRB
  - TRD
  - TRG
  - BCR
  - RN7SL263P
  - CD247
  - CD3D
  - CD3E
  - CD3G
  - CD28
  - PLCB1
  - CD79A
  - CD79B
  - MALT1
  - PRKCB
  - BIRC3
  - MAP3K14
  - MAP4K4
  - LIMA1
  - CRMA
  - BCL10
  - NFKB1
  - SERPINF2
  - FOS
  - FOSB
  - JUN
  - JUNB
  - JUND
  - NFKB2
  - FOSL1
  - FOSL2
---
